European drug regulators are demanding new kidney damage warnings for Tekturna and other drugs containing the active ingredient aliskiren.
The new warnings and contraindications were announced by the European Medicines Agency (EMA) last week.
Tekturna (aliskiren) is manufactured by Novartis and was first approved in the United States in 2007 for the treatment of hypertension.